5 Stocks Pushing The Health Care Sector Higher

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 20 points (-0.2%) at 12,795 as of Monday, Nov. 12, 2012, 11:49 AM ET. The NYSE advances/declines ratio sits at 1,283 issues advancing vs. 1,555 declining with 129 unchanged.

The Health Care sector currently is unchanged today versus the S&P 500, which is down 0.1%. A company within the sector that increased today was Baxter International ( BAX), up 1.0%. A company within the sector that fell today was Express Scripts ( ESRX), up 0.8%.

TheStreet Ratings group would like to highlight 5 stocks pushing the sector higher today:

5. Regeneron Pharmaceuticals ( REGN) is one of the companies pushing the Health Care sector higher today. As of noon trading, Regeneron Pharmaceuticals is up $3.22 (2.3%) to $143.96 on light volume Thus far, 180,127 shares of Regeneron Pharmaceuticals exchanged hands as compared to its average daily volume of 712,100 shares. The stock has ranged in price between $142.24-$144.89 after having opened the day at $142.63 as compared to the previous trading day's close of $140.74.

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines for the treatment of serious medical conditions in the United States. Regeneron Pharmaceuticals has a market cap of $13.0 billion and is part of the drugs industry. The company has a P/E ratio of 69.9, above the S&P 500 P/E ratio of 17.7. Shares are up 148.3% year to date as of the close of trading on Friday. Currently there are 9 analysts that rate Regeneron Pharmaceuticals a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates Regeneron Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and good cash flow from operations. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Regeneron Pharmaceuticals Ratings Report now.

4. As of noon trading, Celgene Corporation ( CELG) is up $3.99 (5.6%) to $75.49 on heavy volume Thus far, 5.1 million shares of Celgene Corporation exchanged hands as compared to its average daily volume of 2.4 million shares. The stock has ranged in price between $74.30-$78.46 after having opened the day at $78.02 as compared to the previous trading day's close of $71.50.

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes various therapies to treat cancer and immune-inflammatory related diseases primarily in the United States and Europe. Celgene Corporation has a market cap of $30.2 billion and is part of the drugs industry. The company has a P/E ratio of 19.8, above the S&P 500 P/E ratio of 17.7. Shares are up 5.8% year to date as of the close of trading on Friday. Currently there are 19 analysts that rate Celgene Corporation a buy, no analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates Celgene Corporation as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, reasonable valuation levels and expanding profit margins. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Celgene Corporation Ratings Report now.

3. As of noon trading, Amgen ( AMGN) is up $0.53 (0.6%) to $85.70 on light volume Thus far, 1.0 million shares of Amgen exchanged hands as compared to its average daily volume of 4.2 million shares. The stock has ranged in price between $84.76-$86.09 after having opened the day at $85.38 as compared to the previous trading day's close of $85.17.

Amgen Inc., a biotechnology medicines company, discovers, develops, manufactures, and markets human therapeutics based on advances in cellular and molecular biology for grievous illnesses primarily in the United States, Europe, and Canada. Amgen has a market cap of $65.0 billion and is part of the drugs industry. The company has a P/E ratio of 15.2, below the S&P 500 P/E ratio of 17.7. Shares are up 32.6% year to date as of the close of trading on Friday. Currently there are 13 analysts that rate Amgen a buy, no analysts rate it a sell, and 12 rate it a hold.

TheStreet Ratings rates Amgen as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, notable return on equity, reasonable valuation levels and compelling growth in net income. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Amgen Ratings Report now.

2. As of noon trading, Eli Lilly and Company ( LLY) is up $0.94 (2.0%) to $48.41 on average volume Thus far, 3.6 million shares of Eli Lilly and Company exchanged hands as compared to its average daily volume of 8.7 million shares. The stock has ranged in price between $47.39-$48.47 after having opened the day at $47.50 as compared to the previous trading day's close of $47.47.

Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products worldwide. Eli Lilly and Company has a market cap of $55.1 billion and is part of the drugs industry. The company has a P/E ratio of 12.9, below the S&P 500 P/E ratio of 17.7. Shares are up 14.2% year to date as of the close of trading on Friday. Currently there are 5 analysts that rate Eli Lilly and Company a buy, 3 analysts rate it a sell, and 7 rate it a hold.

TheStreet Ratings rates Eli Lilly and Company as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, increase in net income, largely solid financial position with reasonable debt levels by most measures, attractive valuation levels and expanding profit margins. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Eli Lilly and Company Ratings Report now.

1. As of noon trading, Gilead ( GILD) is up $7.88 (12.1%) to $72.90 on heavy volume Thus far, 13.9 million shares of Gilead exchanged hands as compared to its average daily volume of 7.0 million shares. The stock has ranged in price between $71.74-$73.25 after having opened the day at $72.31 as compared to the previous trading day's close of $65.01.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes human therapeutics for the treatment of life threatening diseases worldwide. Gilead has a market cap of $49.1 billion and is part of the drugs industry. The company has a P/E ratio of 20.1, above the S&P 500 P/E ratio of 17.7. Shares are up 58.4% year to date as of the close of trading on Friday. Currently there are 20 analysts that rate Gilead a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Gilead as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, reasonable valuation levels, expanding profit margins and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Gilead Ratings Report now.

If you are interested in one of these 5 stocks, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

A reminder about TheStreet Ratings group: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

null

More from Markets

Boeing Slides as China Premier Li Says Willing to Continue Talks With Airbus

Boeing Slides as China Premier Li Says Willing to Continue Talks With Airbus

Stocks Slammed on Latest Trump Tariff Fears

Stocks Slammed on Latest Trump Tariff Fears

Overstock Needs a Catalyst, Says Analyst

Overstock Needs a Catalyst, Says Analyst

American Express Shares Climb After Winning Supreme Court Case

American Express Shares Climb After Winning Supreme Court Case

3 Must Reads on the Market From TheStreet's Top Columnists

3 Must Reads on the Market From TheStreet's Top Columnists